IRWD
NASDAQ · Biotechnology
Ironwood Pharmaceuticals Inc
$4.32
+0.06 (+1.41%)
Financial Highlights (FY 2026)
Revenue
305.84M
Net Income
24.81M
Gross Margin
100.0%
Profit Margin
8.1%
Rev Growth
-10.3%
D/E Ratio
0.61
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 30.9% | 30.9% |
| Operating Margin | 33.3% | 29.9% | 21.9% | 20.5% |
| Profit Margin | 8.1% | 7.7% | 17.0% | 18.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 305.84M | 341.03M | 73.58M | 81.79M |
| Gross Profit | 305.84M | 341.03M | 22.74M | 25.28M |
| Operating Income | 101.72M | 102.08M | 16.11M | 16.74M |
| Net Income | 24.81M | 24.90M | 12.49M | 15.09M |
| Gross Margin | 100.0% | 100.0% | 30.9% | 30.9% |
| Operating Margin | 33.3% | 29.9% | 21.9% | 20.5% |
| Profit Margin | 8.1% | 7.7% | 17.0% | 18.5% |
| Rev Growth | -10.3% | -10.3% | +11.9% | +19.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 134.52M | 134.52M | 202.65M | 191.91M |
| Total Equity | 221.46M | 221.46M | 432.39M | 478.38M |
| D/E Ratio | 0.61 | 0.61 | 0.47 | 0.40 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 103.66M | 109.81M | 23.02M | 27.07M |
| Free Cash Flow | — | — | 13.98M | 17.94M |